Follow the Everest Medicines Ltd. stock price and the full management transaction log of the company, a listed equity based in Hong Kong. Shares are quoted on the HK market, under the oversight of HKEX. Operating in the Health Care sector, Everest Medicines Ltd. has published 21 public disclosures. Market capitalisation: €11.8bn. The latest transaction was filed on 11 September 2026 (Purchase). Among the most active insiders: FU WEI. The full history is openly available.
21
Insider Decl.
n/a
Thresholds
€126m
17 ops.
Buy Volume
n/a
n/a
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Everest Medicines Ltd. Buy (bullish), based on 6 analysts. Average price target: HK$40.66.
36Σ signal
Buys €126mn/a Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 22,320 of 29,064 companies
33.2
score / 100
Value
26
Quality
40
FCF yld-3.7%
Earn yld-2.5%
EV/EBITDA·
ROE-1.2%
Gross mgn69%
Net mgn-17%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.